Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515).
Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM)—in patients with multiple myeloma (Abstract 7546).
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) significantly and relevantly improved long-term quality of life—at the cost of a higher risk of loss or replacement of expander or implant—compared to subpectoral IBBR (Abstract 504).
Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone receptor (HR)-positive, HER2-negative breast cancer, including genomic testing and systemic therapy.
Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515).
